Farmas USA

Bio IPOs desde Q2 2014, y creo que no estan todas

Muy buena esta interpretacion del Precio Objetivo de Wedbush sobre NVAX.

La new de Webbush ( http://www.streetinsider.com/Analyst+Comments/Wedbush+Assumes+Novavax+(NVAX)+at+Outperform/9845410.html )

De un forero usano. Para quien le interese.

http://finance.yahoo.com/mbview/threadview/?&bn=4cc3b79a-3ac0-3136-b6ba-55e126a7836d&tid=1411234398331-da8c0d54-651f-45ff-a51c-1f529df9b38c&tls=la%2Cd%2C1%2C3

So how exactly did Wedbush come up with their $10/share price target?

They gave us three key inputs:

(1) A Revenue model derivation,

(2) A year 2022 Future Value, and

(3) A discount factor of 25% applied over a 7-year period.

For starters, let's peg their 2015 Present Value estimate. I was informed by Management that only 20 of the potential 24M shares from the Company's Stock Option Plan have been issued. So today, the Company's fully-diluted outstanding shares are 258M, not the 262M I used in a previous illustration. So Wedbush is saying that NVAX will have a PV (Year 2015) of $2.58B.

But to get that number, they are saying that NVAX will not realize normalized "run-rate" revenues until the Year 2022. They multiplied that revenue times a factor to get a Future Value. Then they took that FV and discounted it at an enormous 25%/year for seven years to arrive at their PV estimate of $2.58B.

Wedbush came up with a FV in the year 2022 of $12.302B. (This number divided by 258M shares is the $47.68 Jack alluded to in a previous post.) So what would happen if we made two simple adjustments to THEIR model? The two adjustments I have in mind are: (1) Use the Year 2020 for the revenue run-rate (I believe Year 2022 for this purpose is unreasonable), and (2) Apply a 20% discount factor. (I believe the 25% factor applied by Wedbush is WAY over the top and suggests a risk level that is not appropriate here.)

By making these two small adjustments to THEIR model, it causes the Year 2015 PV to rise to $4.944B from $2.58B. That increases their target price from $10/share in 2015 to $19.16/share. Wedbush knows of course that some of their key assumptions are way to conservative. But they also know its too early in the game to come out with a $20 price target. I believe they won't come out with that target until June, 2015.

NVAX

Ana sucede más eso cuando hacemos un seguimiento exhaustivo del AF y caemos en el mismo estado mental de la primera fase del luto donde-Es verdad pero no me lo creo" y vemos la acción caer y caer pero nos congelamos frente a,la pantalla, el AF nos ha ilusionado tanto,..... a muchos le pasó lo mismo el 11 /S, personalmente he tenido 2 veces esa ex experiencia con 2 a las que tambien les hice mxo AF
Lee aquí La creencia limitante"
----https://www.rankia.com/blog/ea-expert-advisors/716658-psicologia-trading-ii-creencias-
--
ACTD

articulo farmas-ebola
http://www.finanzas.com/noticias/empresas/20140922/farmacos-contra-ebola-donde-2756314.html

Y no nombran a HEB! Que poca vergüenza!

DVAX
A Market Good News
--http://www.nasdaq.com/newscontent/20140922\ACQINW201409220600MRKTWIREUSPRX____1146087.htm - Sent from QFolio for Android
---
Claro, claro por eso cerró al alza con enorme paketon de titulos en los últimos 15 mnts y hoy es que publican la noticia,información privilegiada y después se critica al MAB

Premarket, 280 acciones. -20% AMRN.
como se pasan 🙈

ACTCD

Conclusión del artículo de SA: no tiene pies ni cabeza pero con suerte nos dará oportunidad de entrada. Al loro hoy.